Undetectable With Long-Acting, User-Friendly Injectable HIV Medications
August 2, 2016
Two long-acting injectable antiretrovirals administered once every 4 or 8 weeks maintained undetectable viral load in people who switched from a daily oral regimen, researchers reported at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa. People who used the injectables said getting shots was worthwhile and they liked not having to think about HIV treatment every day.
Long-acting injectables could offer an attractive option for people with HIV facing a lifetime of antiretroviral therapy (ART). Some people may find it easier and more convenient to get a shot once a month than to remember to take their pills each day. But the potential drawback of this kind of treatment is that long-acting drugs cannot be removed from the body if problems occur.
David Margolis, M.D., from ViiV Healthcare (abstract THAB0206LB) presented findings from the LATTE-2 trial, which tested a maintenance regimen using injectable formulations of ViiV's experimental integrase inhibitor cabotegravir and the approved NNRTI rilpivirine (an injected formulation of the Edurant pill).
This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.
This article was provided by BETA. It is a part of the publication The 21st International AIDS Conference (AIDS 2016). Visit their website at www.betablog.org.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.